GPLD2 Antibody (N-term) Blocking Peptide

GPLD2 Antibody (N-term) Blocking Peptide

€363.00
In stock
SKU
AC-BP2461a
Catalog Number: AC-BP2461a
Size: 500 µg
Datasheet
Request Information
Background:
Glycosylation is one of the most universal but at the same time complex protein modifications. Modification with sugar moeties can be both co- translational and post- translational, occurring in the endoplasmatic reticulum and golgi. Three different forms of glycosylation can be distinguished: N-linked oligosaccharides, O-linked oligosaccharides and glycosyl- phosphatidylinositol (GPI-) anchors. Glycosylation results in thousands of distinct, bioactive glycoproteins resident throughout the cell that strongly determine protein-protein, carbohydrate-protein, membrane, and adhesion properties. Diseases associated with glycosylation defects include Congenital disorders of glycosylation, (CDG), also known as carbohydrate deficient glycoprotein syndromes, and diseases associated with advanced aging.

Other Names:
Phosphatidylinositol-glycan-specific phospholipase D, PI-G PLD, Glycoprotein phospholipase D, Glycosyl-phosphatidylinositol-specific phospholipase D, GPI-PLD, GPI-specific phospholipase D, GPLD1, PIGPLD1

Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP2461a was selected from the N-term region of human GPLD2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Gene Name: GPLD1

Gene ID: 2822
Primary Accession: P80108
Other Accession: Q15127
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
More Information
Is Featured? No
Write Your Own Review
You're reviewing:GPLD2 Antibody (N-term) Blocking Peptide